DNLI News and Press, Denali Therapeutics Inc. From 05/09/24

2024-05-09 13:22:28 ET More on Novo Nordisk The FTC Cracks Down On Novo Nordisk's Ozempic Novo Nordisk A/S 2024 Q1 - Results - Earnings Call Presentation Novo Nordisk A/S (NVO) Q1 2024 Earnings Call Transcript Catalent, Novo Nordisk receive FTC request for mo...

2024-05-07 17:47:39 ET More on Denali Therapeutics Denali: Leveraging Transport Vehicle Technology For Neurological Gains Denali spikes after $500M private placement Denali slips as Sanofi fails in mid-stage trial for ALS therapy Seeking Alpha’s Quant ...

SOUTH SAN FRANCISCO, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative diseases and lysosomal sto...

SOUTH SAN FRANCISCO, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative and lysosomal storage dise...

2024-04-20 21:14:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-04-12 12:02:53 ET More on AbbVie, Biogen, etc. AbbVie: Despite The Run, Shares Still Look Attractive, Yielding 3.67% Novo Nordisk: The Moat Won't Last Forever AbbVie: Still Fits Buffett's 10x EBT Rule Well Despite Guidance Revision No link between weight...

2024-04-01 01:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-03-22 16:17:17 ET More on Denali Therapeutics Denali: Leveraging Transport Vehicle Technology For Neurological Gains Denali spikes after $500M private placement Denali slips as Sanofi fails in mid-stage trial for ALS therapy Read the full article on Se...

2024-03-09 03:59:00 ET Summary Jared Ablass, Vice President, Portfolio Research at TD Asset Management, speaks with Greg Bonnell about how the biotech sector could benefit once rates start to come down. Why beaten down Biotech stocks could be ready for a healthy recovery. Biot...

2024-03-06 22:05:07 ET Summary Denali's stock performance has been flat despite the biotech sector's 20% rise; recently raised $500 million in a PIPE. ALS trial failure with partner Sanofi pressured stock; Denali's focus is on transport vehicle (TV) technology and BBB crossing. ...